LAG3 and neoplasm: This is exemplified by recent observations made in our lab, where LAG-3 blockade alone did not provide a survival advantage to mice bearing 4T1/MC38 tumours, likely due to low tumour immunogenicity resulting in the absence of an immune response requiring regulation.